Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 1 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 22 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Flindr Labs from Gent, company number BE1014117578, closed financial year 2025 with a result of € -591,098 after tax. For that financial year Flindr Labs recorded a gross margin of € 294,811 and equity of € -391,098. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 23, 2026.
€ -391,098
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -591,098
Profit after tax over the fiscal year.
€ 39,260
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -591,098.
People and assets in 2025
4.2
Average over the fiscal year, from the social balance sheet.
€ 488,411
€ 116,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 10,037
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 24,183
Supplier invoices still open on the last day of the fiscal year.
€ 30,474
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
What happened to Flindr Labs?
What happened at Flindr Labs in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 591,098. Source: NBB ↗
- New establishment in Gent. KBO
- Flindr Therapeutics B.V. became a director. NBB
- Start of the company according to the CBE. KBO
In short
On average € 70,200 of value added per employee in 2025.
Management
Behind Flindr Labs is Flindr Therapeutics B.V..
Directors
According to the 2025 annual accounts
Director · represented by Maarten Alexander Ligtenberg
since 2024
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 94
9052 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.
All companies at this address →ILiAD Biotechnologies
€ 1.4 million gross margin · 2025
Zomagen Biosciences Belgium
€ 1.2 million gross margin · 2025
AnimAb
€ 28,596 gross margin · 2025
ExeVir Bio
€ -1.2 million gross margin · 2025
Protealis
€ 1.1 million gross margin · 2025
+2 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 1014.117.578
- VAT number
- BE 1014.117.578
- Registered office
- Technologiepark-Zwijnaarde 94, 9052 Gent
- Names & denominations
- Flindr Labs
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 25 September 2024
- Peppol
- Active · Active since 9 Dec 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van geneesmiddelen
Vervaardiging van overige farmaceutische producten
Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren
Groothandel in farmaceutische en medische artikelen